Metformin Hydrochloride/Ertugliflozin

盐酸二甲双胍/艾托格列净

Report date: 2022/08/09 18:06:01

Base Information

Drug NameMetformin Hydrochloride/Ertugliflozin
Drug Alias NameSeglurometMK 8835/metforminMK 8835B
ClassificationSmall molecules
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Sodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/12/19
Country/TerritoryUnited StatesIndiaEU +[4] 
CombinationsYes Metformin HydrochlorideErtugliflozin
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesHumanis Saglık Anonim SirketiMerck Sharp & Dohme CorpMerck Sharp & Dohme Bv +[4] 
Inactive CompaniesPfizer IncMerck Sharp & Dohme LLC
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD23
Related LinksN/A